Rescue Therapeutics Inc. is developing a small molecule to improve sensitivity to Doxil doxorubicin chemotherapy in advanced ovarian cancer. The company's RTI-79 could be used to treat a broader population than a more advanced compound that is under review in Europe.

RTI-79, which is in preclinical development, also could be effective in combination with other chemotherapeutic agents and for other solid and hematological cancers.